Cáncer de vejiga

  1. Chara Velarde, L. 1
  2. Bernier García, L. 1
  3. Nalda Arija, I. 1
  4. Peñas Pita da Veiga, M. 1
  5. Cassinello Espinosa, J. 1
  1. 1 Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2021

Zenbakien izenburua: Enfermedades oncológicas (III) Tumores genitourinarios

Saila: 13

Zenbakia: 26

Orrialdeak: 1441-1453

Mota: Artikulua

DOI: 10.1016/J.MED.2021.02.012 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Garapen Iraunkorreko Helburuak

Laburpena

Bladder cancer is the ninth most frequent neoplasm in the world and the most frequent urinary tract cancer. The most important risk factor is tobacco use in addition to environmental exposure to carcinogens. The most habitual symptom is hematuria. Nonmuscle-invasive bladder cancer includes stages pTa and pT1, although they are two entities with different clinical courses. Their treatment involves transurethral resection (TUR) of the bladder and, depending on the risk stratification, adjuvant intravesical instillation of chemotherapy or immunotherapy as well. Nonmetastatic muscle-invasive bladder cancer is treated with a radical cystectomy and administration of perioperative cisplatin-based chemotherapy. In select cases, multimodal treatment for bladder preservation is an alternative. In metastatic disease, treatment is based on cisplatin-based chemotherapy, immunotherapy, and other new tyrosine kinase inhibitor (TKI) agents and conjugated antibodies.

Erreferentzia bibliografikoak

  • Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-93.
  • Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3:327-40.
  • Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration commit-tee of the Japanese Urological Association. Int J Urol. 2009;16:64-9.
  • Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular char-acteristics of bladder cancer in young patients. J Urol. 1998;159:1493-6.
  • Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-37.
  • Schulz MR, Loomis D. Occupational bladder cancer mortality among racial and ethnic minorities in 21 states. Am J Ind Med. 2000;38:90-8.
  • Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcino-genesis. Clin Cancer Res. 2005;11:6512-9.
  • Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogel-stein B. Clonal origin of bladder cancer. N Engl J Med. 1992;326:737-40.
  • Kogevinas M, Mannetje A, Cordier S, Ranft U, González CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Can-cer Causes Control. 2003;14:907-14.
  • Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006;391:603-13.
  • Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Ab-net CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737-45.
  • Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy Cigarette Smoking and Aggressive Bladder Cancer at Initial Presentation. Urology. 2015;86:968-72.
  • Jiang X, Yuan JM, Skipper PL, Tannenbaum SR, Yu MC. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res. 2007;67:7540-5.
  • Jung I, Messing E. Molecular mechanisms and pathways in bladder can-cer development and progression. Cancer Control. 2000;7:325-34.
  • Pira E, Piolatto G, Negri E, Romano C, Boffetta P, Lipworth L, et al. Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up. J Natl Cancer Inst. 2010;102:1096-9.
  • Gago-Domínguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer. 2001;91:575-9.
  • Villanueva CM, Fernández F, Malats N, Grimalt JO, Kogevinas M. Me-ta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003;57:166-73.
  • Moore LE, Smith AH, Eng C, Kalman D, DeVries S, Bhargava V, et al. Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst. 2002;94:1688-96.
  • Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med. 1999;340:1390-7.
  • Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204: 217-23.
  • Kleinerman RA, Boice JD, Jr., Storm HH, Sparen P, Andersen A, Pukkala E, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer. 1995;76:442-52.
  • Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1995;87:524-30.
  • Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, Heaney J, et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 2007;7:13.
  • Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol. 2001;166:2129-33.
  • Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltrans-ferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to blad-der cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev. 1997;6:225-31.
  • Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospec-tive analysis of 1,930 patients with hematuria to evaluate current diagnos-tic practice. J Urol. 2000;163:524-7.
  • Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology. 2001;57:599-603.
  • Marshall VF. Current clinical problems regarding bladder tumors. Can-cer. 1956; 9:543-50.✔29. • Bochner BH, Hansel DE, Efstathiou JA, et al. Urinary bladder. En: Amin MB, editor; AJCC. Cancer staging manual. 8th ed. New York: Springer; 2017. p. 757.
  • Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol. 2016;70:106-19.
  • Tosoni I, Wagner U, Sauter G, Egloff M, Knönagel H, Alund G, et al. Clinical significance of interobserver differences in the staging and grad-ing of superficial bladder cancer. BJU Int. 2000;85:48-53.
  • Sauter G, Mihatsch MJ. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol. 1998;185:339-41.
  • Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-inva-sive bladder cancer (TaT1 and carcinoma in situ) - 2019 Update. Eur Urol. 2019;76:639-57.
  • Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57:2860-4.
  • Dalkilic A, Bayar G, Kilinc MF. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients. Urol J. 2019;16:37-43.
  • Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5; discussion 475-67.
  • Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019;37:61-83.
  • Todenhofer T, Stenzl A, Schwentner C. Optimal use and outcomes of orthotopic neobladder reconstruction in men and women. Curr Opin Urol. 2013;23:479-86.
  • Bochner BH, Dalbagni G, Marzouk KH, Sjoberg DD, Lee J, Donat SM, C, et al. Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes. Eur Urol. 2018;74:465-71.
  • Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391:2525-36.
  • Steven K, Poulsen AL. Radical cystectomy and extended pelvic lympha-denectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol. 2007;178:1218-23; discussion 1223-14.
  • Mandel P, Tilki D, Eslick GD. Extent of lymph node dissection and recu-rrence-free survival after radical cystectomy: a meta-analysis. Urol Oncol. 2014;32:1184-90.
  • Bruins HM, Veskimae E, Hernández V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncolo-gic outcomes in patients undergoing radical cystectomy for bladder can-cer: a systematic review. Eur Urol. 2014;66:1065-77.
  • Mischinger J, Abdelhafez MF, Rausch S, Todenhöfer T, Neumann E, Auf-derklamm S, et al. Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder recons-truction: Studer-pouch versus I-pouch. Eur J Surg Oncol. 2018;44:178-84.
  • Gakis G, Stenzl A. Ileal neobladder and its variants. Eur Urol Suppl. 2010;9:745-53.
  • James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477-88.
  • George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al. Clini-cal outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology. 2004;64:488-93.
  • Sumiyoshi Y. Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. Int J Clin Oncol. 2004; 9:484-90.
  • Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advan-ced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202-5; discussion 205-6.
  • Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gem-citabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol. 2018;36:1949-56.
  • Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bell-munt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014;66:529-41.
  • Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant che-motherapy. Eur Urol. 2017;72:544-54.
  • Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400-10.
  • Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Roth-man AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42-54.
  • Kim DK, Lee JY, Jung JH, Hah YS, Cho KS. Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investig Clin Urol. 2019;60:64-74.
  • Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Can-cer Disease Site Group. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Can J Urol. 2002;9:1625-33.
  • Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Ragha-van D, et al. Long-term follow-up of a phase III intergroup study of cis-platin alone or in combination with methotrexate, vinblastine, and doxo-rubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-9.
  • Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17: 3173-81.
  • Loriot Y, Necchi A, Park SH, García-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338-48
  • Lorenzo-Romero JG, Salinas-Sánchez AS, Giménez-Bachs JM, Sánchez-Sánchez F, Escribano-Martínez J, Segura-Martín M, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol. 2003;169:492-9.
  • Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann On-col. 2007;18:522-8.
  • Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12: 211-4.
  • Loehrer PJ, Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tan-nock I, et al. A randomized comparison of cisplatin alone or in combina-tion with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-73.
  • von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: re-sults of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-77.
  • De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191-9.
  • Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial can-cer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483-92.
  • Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67-76.
  • Galsky MD, Arija JAA, Bamias A, Davis ID, De Santis M, Kiku-chi E, et al. Atezolizumab with or without chemotherapy in metas-tatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1547-57.
  • Meluch AA, Greco FA, Burris HA, 3rd, O’Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19:3018-24.
  • Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218-30.
  • Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015-26.
  • Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial car-cinoma (IMvigor211): a multicentre, open-label, phase 3 randomi-sed controlled trial. Lancet. 2018;391:748-57.
  • Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312-22.
  • Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkmate 032 nivolumab 1 mg/kg plus ipilimu-mab 3 mg/kg expansion cohort results. J Clin Oncol. 2019;37:1608-16.
  • Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal Trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 the-rapy. J Clin Oncol. 2019;37:2592-600.
  • Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61.
  • Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Prac-tice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25Suppl3:iii40-8. doi: 10.1093/annonc/mdu223.
Datuen iturria: Dialnet